Expert Highlights Use of CAR T-Cell Therapy in DLBCL

There has been activity with chimeric antigen receptor (CAR) T cells in patients with relapsed diffuse large B-cell lymphoma (DLBCL), but Charalambos (Babis) Andreadis, MD, MSCE, says there are still several things to consider before choosing this treatment option for a patient.

“It’s something that we’re very excited about, especially for patients with relapsed disease. We also need to remember that it doesn’t work for everyone, and it’s not available to everyone,” said Andreadis. “It’s limited by significant financial considerations and coverage. Even in the patient who can get it, it works about one-third of the time. There’s still room for improvement of CAR T-cell therapy with either new CAR designs or with the addition of adjunctive treatments.”

In October 2017, the FDA approved the CD19-directed CAR T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

Read more at: